AIM 2- Prevention of Neonatal Abstinence Syndrome
Latest Information Update: 09 Jun 2022
At a glance
- Drugs Ondansetron (Primary) ; Ondansetron (Primary)
- Indications Neonatal abstinence syndrome
- Focus Therapeutic Use
- Acronyms AIM2NAS
- 20 Sep 2021 Status changed from active, no longer recruiting to completed.
- 06 May 2021 Planned End Date changed from 31 Jul 2021 to 30 Jun 2021.
- 11 Feb 2021 Planned End Date changed from 1 Feb 2021 to 31 Jul 2021.